Drug combinations in the treatment of neuropathic pain

Current Pain and Headache Reports

Volumn 18, Issue 12, 2014, Pages 1-8

  Eisenberg, Elon ^a   Suzan, Erica ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anticonvulsants; Antidepressants; Neuropathic pain; Opioids; Pain mechanisms

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BENZATROPINE; CALCITONIN; CAPSAICIN; CARBAMAZEPINE; DOXEPIN; DULOXETINE; GABAPENTIN; GLYCERYL TRINITRATE; KETAMINE; LORAZEPAM; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PLACEBO; PREGABALIN; TRAMADOL; VALPROIC ACID; ANTINEOPLASTIC AGENT; DRUG COMBINATION;

ANALGESIA; ARTICLE; CANCER PAIN; CHEMOTHERAPY INDUCED PAINFUL NEUROPATHY; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DELUSION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HIV RELATED PAINFUL NEUROPATHY; HUMAN; LUMBAR RADICULAR PAIN; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROPATHIC CANCER PAIN; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PAIN INTENSITY; PHANTOM PAIN; POSTHERPETIC NEURALGIA; POSTTRAUMATIC NEUROPATHIC PAIN; RADICULAR PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDER; SOMNOLENCE; SPINAL CORD INJURY PAIN; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; XEROSTOMIA; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; NEOPLASM; NEURALGIA; PAIN RECEPTOR; TREATMENT OUTCOME;

ANALGESICS, OPIOID; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; NEURALGIA; NOCICEPTORS; TREATMENT OUTCOME;

EID: 84948757442     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-014-0463-y     Document Type: Article

References (34)

1. Ventafridda V, Saita L, Ripamonti C, De Conno F. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React. 1985;7: 93-6.
2. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10- year prospective study. Pain. 1995;63:65-76.
3. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. Med Gen Med. 2007;9:36.
4. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13-21. Updated Canadian guidelines for neuropathic pain treatment.
5. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Federation of Neurological Societies. Eur J Neurol. 2010;17:1113-88. Most recent European guidelines for the treatment of neuropathic pain.
6. Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the Middle East region. J Int Med Res. 2010;38(2):295-317.
7. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-81. An important neuropathic pain treatment algorythm.
8. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943. A systematic review and meta-analysis of combinations of treatments for neuropathic pain.
9. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol. 2013;12:1084-95. A review of combination therapy for neuropathic pain. A special emphasis on underlying mechanisms of neuropathic pain.
10. Hughes JP, Chessell I, Malamut R, Perkins M, Bačkonja M, Baron R, et al. Understanding chronic inflammatory and neuropathic pain. Ann N YAcad Sci. 2012;1255:30-44.
11. Yamamoto T, Yaksh TL. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett. 1992;135:67-70.
12. Matthews EA, Dickenson AH. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002;96:633-40.
13. Christoph T, De Vry J, Schiene K, Tallarida RJ, Tzschentke TM. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol. 2011;666:72-9.
14. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 2012;11:999-1005. A new approach for subgrouping paitents with neuropathic pain.
15. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-34.
16. Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12:804-13.
17. Zin CS, Nissen LM, O’Callaghan JP, Duffull SB, Smith MT, Moore BJ. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain. 2010;11:462-71.
18. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909-17.
19. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2009;374:1252-61.
20. Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”—a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616-25.
21. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori. 2002;88:239-42.
22. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain. 2007;130:66-75.
23. Harrison T, Miyahara S, Lee A, Evans S, Bastow B, Simpson D, et al. Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIVassociated polyneuropathies. Pain Med. 2013;14:1039-47.
24. Zhou HY, Chen SR, Pan HL. Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4:379-88.
25. Tonet C, Sakata RK, Issy AM, Garcia JBS, Marcelino ANM. Evaluation of oral ketamine for neuropathic pain [Avaliação da cetamina oral para dor neuropática]. Revista Brasileira de Medicina. 2008;65:214-8.
26. Eichenberger U, Neff F, Sveticic G, Björgo S, Petersen-Felix S, Arendt-Nielsen L, et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg. 2008;106:1265-73.
27. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010;13:245-9.
28. Freeman R, Raskin P, Hewitt DJ, Vorsanger GJ, Jordan DM, Xiang J, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23:147-61.
29. McCleane GJ. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett. 2003;338:151-4.
30. Lynch ME, Clark AJ, Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain. 2003;19:323-8.
31. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103:140-6.
32. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2000;49:574-9.
33. Agrawal RP, Goswami J, Jain S, Kochar DK. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract. 2009;83:371-8.
34. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19:833-41.